Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in relapsed multiple myeloma after one prior therapy
2009-017930-35Phase 3Completed
- Sponsor
- AB Science
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Masitinib + bortezomib + dexamethasone with Placebo + bortezomib + dexamethasone (2 arms). Primary endpoint: Overall progression-free survival. Started Mar 2010; status: completed.
02
Drugs
masitinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-017930-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017930-35.